| Metric | Value (₹ Cr) | Q1 FY27 | Q2 FY26 |
|---|---|---|---|
| Revenue | 1.6K | 12.8% | 36.2% |
| Total Income | 1.6K | 12.9% | 36.1% |
| Expenditure | 1.5K | 13.1% | 38.3% |
| PBT | 99.87 | 10.3% | 9.7% |
| Net Profit | 123.97 | 14.7% | 79.6% |
| OPM | 8.76% | 0.05pp | 0.80pp |
| NPM | 7.68% | 0.12pp | 1.86pp |
| EPS | 6.80 | 12.2% | 41.4% |
Detailed report is being prepared.
Expansion into ADAS and Seating Drives Valuation — Can Margins Hold?
Gabriel reports Q2 FY27 amid aggressive JV buildout. Street expects steady auto-demand earnings, but the real test: whether ₹1000 Cr in new debt and capex for HL Klemove/Faurecia can scale without margin compression.
The Setup: Gabriel India enters Q2 FY27 having pivoted from a pure-play suspension supplier into a multi-business mobility tech platform. Three major moves in the past two months — a $98.44 million (₹935 Cr) stake in HL Klemove for autonomous driving systems, a 50-minus-one seating JV with Faurecia, and a ₹1000 Cr debt raise — have transformed the earnings profile. The question is not whether Gabriel can grow, but whether near-term profitability holds as capex and JV ramp cycle in.
What to Expect
~₹350 Cr
14% YoY growth expected, in line with FY27 guidance trajectory; Q1 FY27 set the base
~13%
Stable vs. Q1; JV equity pickup (not consolidation) means profit contribution modest in early ramp
~₹30 Cr
EPS ~₹5.2–5.4; growth intact despite ₹1000 Cr NCD burden (mostly post-quarter funding)
~1.2x–1.4x
Post NCD issue; key risk if H2 capex continues without offsetting JV EBITDA lift
A strong quarter would show: revenue growth in the 14–16% YoY range, EBITDA margin stable or +30–50 bps despite JV investment, and clear guidance that HL Klemove will deliver meaningful EBITDA by Q3/Q4. A weak quarter would reveal: margin compression below 12%, stalled growth momentum, or a cautious Q3–Q4 outlook citing JV integration drag. The median case — and what's priced in — is steady-as-she-goes: earnings growth in the mid-teens, margins held, and a dividend to back capital discipline.
Is Gabriel on Track?
Yes, operationally. Q1 FY27 set a strong tone: revenue growth, EPS in the ₹5+ range, and no margin slip despite large acquisition activity. Guidance for FY27 calls for ~22.7% earnings growth and ~17.5% revenue growth; Q2 tracking so far supports this, assuming no fresh external shocks. The worry is capital deployment risk: Gabriel has committed ₹935 Cr to HL Klemove and is raising ₹1000 Cr fresh debt. If the JVs don't hit their profit targets on schedule, or if execution slips, leverage could become a near-term headwind. Interim dividend approval signals management confidence in cash generation and discipline.
What the Street Says
Since Last Quarter
1 · Strategic JV Buildout (Aug–Oct 2026)
HL Klemove 30% stake acquisition completed for $98.44 Mn (₹935 Cr); Faurecia seating JV incorporated Oct 19. These are multi-year, high-margin revenue pools being grafted onto a mature auto-components base. Early indicators: both JVs moving to develop, not just explore. Gabriel's capex cycle has shifted upmarket.
2 · Debt & Liquidity Move (Aug–Sep 2026)
₹1000 Cr Non-Convertible Debenture issuance approved and allotted in Sep, tagged as senior unsecured. Proceeds earmarked for JV funding and working capital. Leverage metrics now on watch; Q2 result will be first hard data on debt service and cash generation post-raise.
3 · Dividend & Capital Allocation (Oct 2026)
Board to consider interim dividend on Oct 30 (record date Nov 6). Signals cash surplus and management discipline despite ₹935 Cr capex outflow. This is a positive signal for shareholder faith.
4 · Promoter Stake Move (Sep 2026)
Asia Investments Pvt Ltd (promoter) acquired 1.44 Cr shares via preferential allotment in Sep, raising promoter stake from 55.0% to 63.55% QoQ. No cash consideration; part of internal capital management. Insider buying is a positive signal, though structure should be monitored for future dilution risk.
5 · Price Movement (Sep 2026)
Stock saw significant intra-quarter volatility (Sep 23: BSE asked for reason for price spike; Gabriel stated 'unaware of any specific reason'). Routine clarification, but highlights that JV announcements have moved sentiment sharply. No red flags, just expected volatility in growth-story transitions.
What to Watch on Result Day
1. Margin resilience: Any EBITDA margin below 12.5% would signal JV capex is dragging forward profits too early. Target: 13–14% EBITDA margin, in line with historical run-rate. 2. JV contribution & outlook: Management will likely guide on HL Klemove ramp (1–2 year to breakeven expected for most JVs). Clarity on profit takeup schedule is critical. 3. Debt service & FCF: With ₹1000 Cr fresh debt, CFO comments on leverage ratios, debt-to-EBITDA targets, and H2 FY27 capex intensity will set the tone for near-term re-rating. 4. Full-year guidance: Expect reaffirmation of 22–23% earnings growth and 17–18% revenue growth for FY27, or a tactical reset if JV ramps slip.
Gabriel India is executing a high-stakes pivot from component supplier to diversified mobility-tech platform. The HL Klemove ADAS and Faurecia seating JVs are strategically sound — both fill gaps in the product stack and tap high-growth segments. The challenge is timing: ₹935 Cr has left the balance sheet, ₹1000 Cr of new debt has arrived, and the Street is pricing in flawless integration and near-term margin stability. Q2 FY27 will show whether that thesis is holding or beginning to crack. Expect a beat or in-line result on earnings; the debate will be about margins, JV ramp pace, and full-year leverage comfort. For growth investors, this is a 'prove-it' quarter. For value investors watching execution risk, it's the quarter to reassess the debt/capex cycle.